Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.60 |
| ▸ | BCHE | P06276 | 11/20 | 0.57 |
| ▸ | ACHE | P22303 | 10/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220464 | 1.00 | ABCG2 (0.60) | ABCG2BCHEACHEHRH3MAOB | |
| SCHEMBL2220468 | 1.00 | ABCG2 (0.60) | ABCG2BCHEACHEHRH3MAOB | |
| SCHEMBL25191766 | 0.93 | ABCG2 (0.67) | ABCG2BCHEACHEHRH3MAOB | |
| SCHEMBL25204473 | 0.91 | ABCG2 (0.60) | ABCG2BCHEACHEHRH3MAOB | |
| SCHEMBL25204475 | 0.91 | ABCG2 (0.60) | ABCG2BCHEACHEHRH3MAOB | |
| SCHEMBL20608176 | 0.88 | ABCG2 (0.70) | ABCG2BCHEACHEHRH3MAOB | |
| SCHEMBL18481042 | 0.88 | ABCG2 (0.70) | ABCG2BCHEACHEHRH3MAOB | |
| SCHEMBL25209362 | 0.87 | ABCG2 (0.60) | ABCG2BCHEACHEHRH3MAOB | |
| SCHEMBL7058879 | 0.87 | MAOB (0.70) | ABCG2BCHEACHEMAOB | |
| SCHEMBL2993330 | 0.87 | MAOB (0.68) | ABCG2BCHEACHEHRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-8362151-B2 | Hybrid polymer materials for liquid crystal alignment layers | ELSICON, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362151-B2 | Hybrid polymer materials for liquid crystal alignment layers | ELSICON, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2011084546-A1 | HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS | LI CHUNHONG (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20100305230-A1 | HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS | ELSICON, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305230-A1 | HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS | ELSICON, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100103358-A1 | HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS | ELSICON, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100103358-A1 | HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS | ELSICON, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-7632875-B2 | Hybrid polymer materials for liquid crystal alignment layers | ELSICON, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632875-B2 | Hybrid polymer materials for liquid crystal alignment layers | ELSICON, INC. (US) | 2009-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | ABCG2 1606/4885BCHE 588/4885ACHE 806/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885BCHE 465/4885ACHE 656/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885BCHE 465/4885ACHE 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.